Browse the evidence

Patients exhibited initial physical functioning scores below the reference values yet demonstrated substantial physical recuperation by the 12-week mark following their ICU discharge in both groups.

Nutrition interventions may play a crucial role in recovery for post-ICU patients.

Moderate-quality evidence revealed beneficial relationships between the intake of omega-6 fatty acids and cardiovascular disease (CVD) mortality, overall cancer mortality, and all-cause mortality.

Increasing omega-6 fatty acid intake may reduce risks of CVD and cancer.

Moderate-quality evidence suggested that seafood-derived omega-3 fatty acids were associated with reduced triglyceride levels, elevated high density lipoprotein cholesterol, and a decreased risk of coronary heart disease.

Encouraging seafood consumption may improve heart health and lipid profiles.

Myofibrillar protein synthesis rates did not differ between omnivorous and vegan dietary patterns.

Both omnivorous and vegan diets can support similar rates of muscle protein synthesis during resistance training.

Tirzepatide is linked to a significantly reduced risk of overall hematologic malignancy (OR = 0.14, 95%CI = 0.03-0.60), particularly for lymphoma.

Tirzepatide may be a safer option for patients concerned about hematologic malignancies.

GLP-1 receptor agonists (GLP-1RAs) may influence skeletal muscle through anti-inflammatory, antioxidant, and mitochondrial-supportive mechanisms.

Practitioners should consider the potential muscle-preserving effects of GLP-1RAs in patients at risk for sarcopenia.

GLP-1RAs have shown muscle-preserving properties in experimental models of aging, sarcopenic obesity, and chronic disease.

GLP-1RAs may be beneficial in preserving muscle in specific populations, such as the elderly or those with chronic diseases.

Visceral and ectopic fat accumulation strongly predicts adverse lipid patterns, insulin resistance, and cardiovascular events.

Focus on reducing visceral and ectopic fat to improve lipid profiles and reduce cardiovascular risk.

MNs hold promise in improving the quality of life for individuals struggling with obesity and its associated comorbidities.

MNs may enhance treatment efficacy and patient outcomes in obesity management.

Sarcopenia is characterized by the progressive and generalized loss of muscle mass and strength, negatively impacting health and quality of life.

Understanding sarcopenia is crucial for developing interventions to improve health in aging populations.

Bone mineral content (BMC) increased during the weight loss period, leading to a smaller reduction in fat-free mass (FFM) compared to LST.

Practitioners should note the increase in BMC during weight loss, which may influence overall body composition assessments.

The effects of resistance training at longer muscle lengths show an increasing trend from proximal to distal sites.

Practitioners may consider the trend when designing resistance training programs, but should note the trivial nature of the differences.

GLP-1 receptor agonists (GLP-1RAs) may help manage psoriasis (PsO) and psoriatic arthritis (PsA) in patients with obesity.

Clinicians may consider GLP-1RAs as a treatment option for obese patients with PsO and PsA.

The degree of muscle-based losses varied widely among the incretin groups.

Individual responses to incretin therapies can vary, necessitating personalized treatment approaches.

Intensive glycemic control can precipitate hypoglycemic events, which may lead to serious complications.

Healthcare providers should monitor patients closely to prevent hypoglycemic events during intensive glycemic control.

Metabolic disorders such as obesity, type 2 diabetes, and dyslipidaemia are major drivers of cardiovascular risk.

Practitioners should focus on addressing metabolic disorders to reduce cardiovascular risk.

New pharmacological approaches aim to conserve lean body mass during weight loss.

Emerging drugs may help maintain muscle mass during weight loss, which is crucial for long-term success.

GLP-1 receptor agonists are approved for steatotic liver disease, with demonstrated histologic and biochemical benefits.

GLP-1 receptor agonists can be utilized in clinical practice for managing steatotic liver disease effectively.

Ingestion of a single bolus of hydrolyzed collagen or free amino acids substantially increases circulating amino acids concentrations, particularly glycine.

Practitioners can consider collagen and amino acid supplementation to enhance amino acid availability post-exercise.

Plasma essential amino acid concentrations increased after protein ingestion, but did not differ between recombinant bovine β-lactoglobulin (rBLG) and whey.

Both rBLG and whey can effectively increase amino acid levels post-ingestion, making them viable protein sources.

Obesity initiates the development of insulin resistance through increased adipose tissue size, inflammation, and ectopic fat deposition.

Understanding the role of obesity in insulin resistance can guide interventions.

Inflammation and fat accumulation are key drivers for losing insulin sensitivity.

Addressing inflammation and fat accumulation may improve insulin sensitivity.

Weight loss, regardless of the method used to achieve it, is inadvertently accompanied by lean body mass loss, to varying degrees.

Practitioners should be aware that weight loss methods may lead to loss of lean body mass.

The loss of lean body mass, including muscle, is a significant concern associated with weight loss treatments.

Practitioners should monitor muscle mass during weight loss interventions.